Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

EPIC Nitinol Stent System in the Treatment of Atherosclerotic Lesions in Iliac Arteries

Study:

A Boston Scientific Trial of the EPIC™ Nitinol Stent System in the Treatment of Atherosclerotic Lesions in Iliac Arteries

Rationale:

n/a

Purpose:

The ORION study is being conducted to determine whether the Epic™ Nitinol Stent for primary stenting of iliac atherosclerotic lesions shows acceptable performance at 9 months.

Study Status: Active, not recruiting

Recruiting:
n/a

Condition Intervention Phase
Iliac Artery Stenosis Device: Epic™ Nitinol Stent System
Drug: Anti-platelet therapy
Drug: Anti-coagulation therapy
Phase 3

Verified by Boston Scientific Corporation July, 2012

Sponsored by: Boston Scientific Corporation
Information provided by: Boston Scientific Corporation
ClinicalTrials.gov identifier: NCT00896337

Study Type: Interventional

Study Design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic
Cleveland, Ohio 44195
United States

Pamela G. Grady, Ph.D.., Study Director
Daniel G Clair, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site